Targets for pharmacological intervention of endothelial hyperpermeability and barrier function

Vascular Pharmacology

Volumn 39, Issue 4-5, 2002, Pages 257-272

  Van Nieuw Amerongen, Geerten P ^a   Van Hinsbergh, Victor W M ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Endothelial cells; Pharmacological intervention; Vascular leakage

Indexed keywords

2 AMINO 4 (3 PYRIDYL) 4H NAPHTHO[1,2 B]PYRAN 3 CARBONITRILE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; AE 941; ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; ANTITHROMBIN III; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CD31 ANTIGEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; COMPLEMENT COMPONENT C1S INHIBITOR; CROMOGLYCATE DISODIUM; DOBUTAMINE; DOPEXAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; FASUDIL; GLUCOCORTICOID; H 1152; INTERCELLULAR ADHESION MOLECULE 1; LIPOSOME; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PACLITAXEL; PHOSPHODIESTERASE INHIBITOR; PROTEIN KINASE C BETA; RUBOXISTAURIN; SEMAXANIB; SEROTONIN ANTAGONIST; SIMVASTATIN; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASOACTIVE AGENT; VATALANIB; VIRUS VECTOR; XANTHINE DERIVATIVE; Y 32885; ZM 32881; ENDOTHELIN RECEPTOR; ENZYME INHIBITOR; PROTEIN KINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CELL INTERACTION; CELL TRANSPORT; CLINICAL PRACTICE; DRUG DELIVERY SYSTEM; EDEMA; ENDOTHELIUM CELL; HUMAN; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VENULE; ANIMAL; CAPILLARY PERMEABILITY; CELL JUNCTION; CELL MEMBRANE PERMEABILITY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM;

ANIMALS; CAPILLARY PERMEABILITY; CELL MEMBRANE PERMEABILITY; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; INTERCELLULAR JUNCTIONS; PROTEIN KINASE INHIBITORS; RECEPTORS, ENDOTHELIN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0042845698     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1537-1891(03)00014-4     Document Type: Review

References (160)

1. Abe T., Wakimoto H., Bookstein R., Maneval D.C., Chiocca E.A., Basilion J.P. Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors. Cancer Gene Ther. 9:2002;228-235.
2. Adamson R.H., Curry F.E., Adamson G., Liu B., Jiang Y., Aktories K., Barth H., Daigeler A., Golenhofen N., Ness W., Drenckhahn D. Rho and rho kinase modulation of barrier properties: cultured endothelial cells and intact microvessels of rats and mice. J. Physiol. 539:2002;295-308.
3. Aiello L.P., Bursell S.-E., Clermont A., Duh E., Ishii H., Takagi C., Mori F., Ciulla T.A., Ways K., Jirousek M., Smith L.E.H., King G.L. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes. 46:1997;1473-1480.
4. Arap W., Pasqualini R. The human vascular mapping project. Selection and utilization of molecules for tumor endothelial targeting. Haemostasis. 31(Suppl. 1):1902;30-31.
5. Arap W., Kolonin M.G., Trepel M., Lahdenranta J., Cardo-Vila M., Giordano R.J., Mintz P.J., Ardelt P.U., Yao V.J., Vidal C.I., Chen L., Flamm A., Valtanen H., Weavind L.M., Hicks M.E., Pollock R.E., Botz G.H., Bucana C.D., Koivunen E., Cahill D., Troncoso P., Baggerly K.A., Pentz R.D., Do K.A., Logothetis C.J., Pasqualini R. Steps toward mapping the human vasculature by phage display. Nat. Med. 8:2002;121-127.
6. Asghar S.S., Pasch M.C. Therapeutic inhibition of the complement system. Y2K update. Front. Biosci. 5:2000;E63-E81.
7. Assanasen P., Naclerio R.M. Antiallergic anti-inflammatory effects of H1-antihistamines in humans. Clin. Allergy Immunol. 17:1902;101-139.
8. Basu S., Nagy J.A., Pal S., Vasile E., Eckelhoefer I.A., Bliss V.S., Manseau E.J., Dasgupta P.S., Dvorak H.F., Mukhopadhyay D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat. Med. 7:2001;569-574.
9. Bates D.O., Harper S. Regulation of microvascular permeability by vascular endothelial growth factors. Vasc. Pharmacol. 39:2003;225-237.
10. Beckman J.A., Goldfine A.B., Gordon M.B., Garrett L.A., Creager M.A. Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ. Res. 90:2002;107-111.
11. Beliveau R., Gingras D., Kruger E.A., Lamy S., Sirois P., Simard B., Sirois M.G., Tranqui L., Baffert F., Beaulieu E., Dimitriadou V., Pepin M.C., Courjal F., Ricard I., Poyet P., Falardeau P., Figg W.D., Dupont E. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin. Cancer Res. 8:2002;1242-1250.
12. Bloomfield G.L., Holloway S., Ridings P.C., Fisher B.J., Blocher C.R., Sholley M., Bunch T., Sugerman H.J., Fowler A.A. Pretreatment with inhaled nitric oxide inhibits neutrophil migration and oxidative activity resulting in attenuated sepsis-induced acute lung injury. Crit. Care Med. 25:1997;584-593.
13. Bonetti P.O., Wilson S.H., Rodriguez-Porcel M., Holmes D.R., Lerman L.O., Lerman A. Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. J. Am. Coll. Cardiol. 40:2002;546-554.
14. Brillault J., Berezowski V., Cecchelli R., Dehouck M.P. Intercommunications between brain capillary endothelial cells and glial cells increase the transcellular permeability of the blood-brain barrier during ischaemia. J. Neurochem. 83:2002;807-817.
15. Bruick R.K., McKnight S.L. Building better vasculature. Genes Dev. 15:2001;2497-2502.
16. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., Scholz D., Acker T., DiPalma T., Dewerchin M., Noel A., Stalmans I., Barra A., Blacher S., Vandendriessche T., Ponten A., Eriksson U., Plate K.H., Foidart J.M., Schaper W., Charnock-Jones D.S., Hicklin D.J., Herbert J.M., Collen D., Persico M.G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7:2001;575-583.
17. Carugati A., Pappalardo E., Zingale L.C., Cicardi M. C1-inhibitor deficiency and angioedema. Mol. Immunol. 38:2001;161-173.
18. Chang S.W., Feddersen C.O., Henson P.M., Voelkel N.F. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J. Clin. Invest. 79:1987;1498-1509.
19. Chen, H.X., Gore-Langton, R.E., Cheson, B.D., 2001. Clinical trials referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Huntingt) 15, 1017, 1020, 1023-1017, 1020, 1026.
20. Chiba Y., Ishii Y., Kitamura S., Sugiyama Y. Activation of rho is involved in the mechanism of hydrogen-peroxide-induced lung edema in isolated perfused rabbit lung. Microvasc. Res. 62:2001;164-171.
21. Chow M., Dumont A.S., Kassell N.F. Endothelin receptor antagonists and cerebral vasospasm: an update. Neurosurgery. 51:2002;1333-1342.
22. Ciordia R., Supko J., Gatineau M., Batchelor T. Cytotoxic chemotherapy: advances in delivery, pharmacology, and testing. Curr. Oncol. Rep. 2:2000;445-453.
23. Clauss M., Sunderkotter C., Sveinbjornsson B., Hippenstiel S., Willuweit A., Marino M., Haas E., Seljelid R., Scheurich P., Suttorp N., Grell M., Risau W. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood. 97:2001;1321-1329.
24. Cloughesy T.F., Black K.L. Pharmacological blood-brain barrier modification for selective drug delivery. J. Neuro-oncol. 26:1995;125-132.
25. Colangelo S., Langille B.L., Steiner G., Gotlieb A.I. Alterations in endothelial F-actin microfilaments in rabbit aorta in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 18:1998;52-56.
26. Cooper J.A., Del Vecchio P.J., Minnear F.L., Burhop K.E., Selig W.M., Garcia J.G., Malik A.B. Measurement of albumin permeability across endothelial monolayers in vitro. J. Appl. Physiol. 62:1987;1076-1083.
27. Corada M., Zanetta L., Orsenigo F., Breviario F., Lampugnani M.G., Bernasconi S., Liao F., Hicklin D.J., Bohlen P., Dejana E. A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood. 100:2002;905-911.
28. Cruz K., Hollenberg S.M. Modifying leukocyte endothelial interactions in acute inflammatory models. Crit. Care Med. 30:2002;1924-1925.
29. Curnis F., Arrigoni G., Sacchi A., Fischetti L., Arap W., Pasqualini R., Corti A. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 62:2002;867-874.
30. Curnis F., Sacchi A., Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest. 110:2002;475-482.
31. Dell'Omo G., Bandinelli S., Penno G., Pedrinelli R., Mariani M. Simvastatin, capillary permeability, and acetylcholine-mediated vasomotion in atherosclerotic, hypercholesterolemic men. Clin. Pharmacol. Ther. 68:2000;427-434.
32. Demeule M., Poirier J., Jodoin J., Bertrand Y., Desrosiers R.R., Dagenais C., Nguyen T., Lanthier J., Gabathuler R., Kennard M., Jefferies W.A., Karkan D., Tsai S., Fenart L., Cecchelli R., Beliveau R. High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J. Neurochem. 83:2002;924-933.
33. Dhingra V.K., Uusaro A., Holmes C.L., Walley K.R. Attenuation of lung inflammation by adrenergic agonists in murine acute lung injury. Anesthesiology. 95:2001;947-953.
34. Dickneite G., Kroez M. Treatment of porcine sepsis with high-dose antithrombin III reduces tissue edema and effusion but does not increase risk for bleeding. Blood Coagul. Fibrinolysis. 12:2001;459-467.
35. Doolittle N.D., Miner M.E., Hall W.A., Siegal T., Jerome E., Osztie E., McAllister L.D., Bubalo J.S., Kraemer D.F., Fortin D., Nixon R., Muldoon L.L., Neuwelt E.A. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer. 88:2000;637-647.
36. Doorenbos C.J., van Es A., Valentijn R.M., Van Es L.A. Systemic capillary leak syndrome. Preventive treatment with terbutaline. Neth. J. Med. 32:1988;178-184.
37. Drevs J., Muller-Driver R., Wittig C., Fuxius S., Esser N., Hugenschmidt H., Konerding M.A., Allegrini P.R., Wood J., Hennig J., Unger C., Marme D. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 62:2002;4015-4022.
38. Droder R.M., Kyle R.A., Greipp P.R. Control of systemic capillary leak syndrome with aminophylline and terbutaline. Am. J. Med. 92:1992;523-526.
39. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20:2002;4368-4380.
40. Eibl G., Buhr H.J., Foitzik T. Therapy of microcirculatory disorders in severe acute pancreatitis: what mediators should we block? Intensive Care Med. 28:2002;139-146.
41. Eliceiri B.P., Paul R., Schwartzberg P.L., Hood J.D., Leng J., Cheresh D.A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell. 4:1999;915-924.
42. Elizondo F.G.J., Sung C. Effect of angiotensin II on immunotoxin uptake in tumor and normal tissue. Cancer Chemother. Pharmacol. 39:1996;113-121.
43. Elson D.A., Thurston G., Huang L.E., Ginzinger D.G., McDonald D.M., Johnson R.S., Arbeit J.M. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev. 15:2001;2520-2532.
44. Feng D., Nagy J.A., Hipp J., Dvorak H.F., Dvorak A.M. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J. Exp. Med. 183:1996;1981-1986.
45. Feng D., Nagy J.A., Pyne K., Hammel I., Dvorak H.F., Dvorak A.M. Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation. 6:1999;23-44.
46. Ferrero E., Magni E., Curnis F., Villa A., Ferrero M.E., Corti A. Regulation of endothelial cell shape and barrier function by chromogranin A. Ann. N. Y. Acad. Sci. 971:2002;355-358.
47. Ferri L.E., Pascual J., Seely A.J., Chaudhury P., Christou N.V. Soluble L-selectin attenuates tumor necrosis factor-alpha-mediated leukocyte adherence and vascular permeability: a protective role for elevated soluble L-selectin in sepsis. Crit. Care Med. 30:2002;1842-1847.
48. Fong T.A., Shawver L.K., Sun L., Tang C., App H., Powell T.J., Kim Y.H., Schreck R., Wang X., Risau W., Ullrich A., Hirth K.P., McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:1999;99-106.
49. Friedl J., Puhlmann M., Bartlett D.L., Libutti S.K., Turner E.N., Gnant M.F., Alexander H.R. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood. 100:2002;1334-1339.
50. Funatsu T., Sawa Y., Ohtake S., Takahashi T., Matsumiya G., Matsuura N., Nakamura T., Matsuda H. Therapeutic angiogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor. J. Thorac. Cardiovasc. Surg. 124:2002;1099-1105.
51. Gamble J.R., Drew J., Trezise L., Underwood A., Parsons M., Kasminkas L., Rudge J., Yancopoulos G., Vadas M.A. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ. Res. 87:2000;603-607.
52. Garat C., Jayr C., Eddahibi S., Laffon M., Meignan M., Adnot S. Effects of inhaled nitric oxide or inhibition of endogenous nitric oxide formation on hyperoxic lung injury. Am. J. Respir. Crit. Care Med. 155:1997;1957-1964.
53. Garcia J.G., Liu F., Verin A.D., Birukova A., Dechert M.A., Gerthoffer W.T., Bamberg J.R., English D. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J. Clin. Invest. 108:2001;689-701.
54. Gingras D., Batist G., Beliveau R. AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. Expert Rev. Anticancer Ther. 1:2001;341-347.
55. Grega G.J., Persson C.G.A., Svensjo E. Endothelial cell reactions to inflammatory mediators assessed in vivo by fluid and solute flux analysis. Ryan U.S. Endothelial Cells. 1988;103-119 CRC Press, Boca Raton, FL.
56. Groeneveld A.B.J. Vascular pharmacology of acute lung injury and acute respiratory distress syndrome. Vasc. Pharmacol. 39:2003;247-256.
57. Groothuis D.R. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-oncology. 2:2000;45-59.
58. Gutterman D.D. Vascular dysfunction in hyperglycemia: is protein kinase C the culprit? Circ. Res. 90:2002;5-7.
59. i and permeability in microvessels exposed to ATP. Am. J. Physiol. 265:1993;H1019-H1023.
60. Hempel A., Noll T., Muhs A., Piper H.M. Functional antagonism between cAMP and cGMP on permeability of coronary endothelial monolayers. Am. J. Physiol. 270:1996;H1264-H1271.
61. Hempel A., Lindschau C., Maasch C., Mahn M., Bychkov R., Noll T., Luft F.C., Haller H. Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C. Circulation. 99:1999;2523-2529.
62. Hippenstiel S., Witzenrath M., Schmeck B., Hocke A., Krisp M., Krull M., Seybold J., Seeger W., Rascher W., Schutte H., Suttorp N. Adrenomedullin reduces endothelial hyperpermeability. Circ. Res. 91:2002;618-625.
63. Hoshino M., Takahashi M., Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J. Allergy Clin. Immunol. 107:2001;295-301.
64. Ikenoya M., Hidaka H., Hosoya T., Suzuki M., Yamamoto N., Sasaki Y. Inhibition of rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. J. Neurochem. 81:2002;9-16. (JID-2985190R).
65. Ishihara K., Kamata M., Hayashi I., Yamashina S., Majima M. Roles of bradykinin in vascular permeability and angiogenesis in solid tumor. Int. Immunopharmacol. 2:2002;499-509.
66. Ishizaki T., Uehata M., Tamechika I., Keel J., Nonomura K., Maekawa M., Narumiya S. Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinases. Mol. Pharmacol. 57:2000;976-983.
67. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7:2001;987-989.
68. Jain R.K., Munn L.L. Leaky vessels? Call Ang1! Nat. Med. 6:2000;131-132.
69. Joussen A.M., Poulaki V., Tsujikawa A., Qin W., Qaum T., Xu Q., Moromizato Y., Bursell S.E., Wiegand S.J., Rudge J., Ioffe E., Yancopoulos G.D., Adamis A.P. Suppression of diabetic retinopathy with angiopoietin-1. Am. J. Pathol. 160:2002;1683-1693.
70. Kimura T., Sato K., Kuwabara A., Tomura H., Ishiwara M., Kobayashi I., Ui M., Okajima F. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J. Biol. Chem. 276:2001;31780-31785.
71. Kirschfink M. Targeting complement in therapy. Immunol. Rev. 180:2001;177-189.
72. Krzystolik M.G., Afshari M.A., Adamis A.P., Gaudreault J., Gragoudas E.S., Michaud N.A., Li W., Connolly E., O'Neill C.A., Miller J.W. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 120:2002;338-346.
73. Kubes P., Gaboury J.P. Rapid mast cell activation causes leukocyte-dependent and -independent permeability alterations. Am. J. Physiol. 271:1996;H2438-H2446.
74. Langeler E.G., van Hinsbergh V.W. Norepinephrine and iloprost improve barrier function of human endothelial cell monolayers: role of cAMP. Am. J. Physiol. 260:1991;C1052-C1059.
75. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273:1998;24266-24271.
76. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1998;1129-1135.
77. Lejeune F.J. Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J. Clin. Invest. 110:2002;433-435.
78. Liu Y., Wada R., Yamashita T., Mi Y., Deng C.X., Hobson J.P., Rosenfeldt H.M., Nava V.E., Chae S.S., Lee M.J., Liu C.H., Hla T., Spiegel S., Proia R.L. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest. 106:2000;951-961.
79. Liu F., Schaphorst K.L., Verin A.D., Jacobs K., Birukova A., Day R.M., Bogatcheva N., Bottaro D.P., Garcia J.G. Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3beta. FASEB J. 16:2002;950-962.
80. Lo S.K., Everitt J., Gu J., Malik A.B. Tumor necrosis factor mediates experimental pulmonary edema by ICAM-1 and CD18-dependent mechanisms. J. Clin. Invest. 89:1992;981-988.
81. Lofton C.E., Newman W.H., Currie M.G. Atrial natriuretic peptide regulation of endothelial permeability is mediated by cGMP. Biochem. Biophys. Res. Commun. 172:1990;793-799.
82. Luttun A., Brusselmans K., Fukao H., Tjwa M., Ueshima S., Herbert J.M., Matsuo O., Collen D., Carmeliet P., Moons L. Loss of placental growth factor protects mice against vascular permeability in pathological conditions. Biochem. Biophys. Res. Commun. 295:2002;428-434.
83. Malik A.B., Lo S.K. Vascular endothelial adhesion molecules and tissue inflammation. Pharmacol. Rev. 48:1996;213-229.
84. Masferrer J.L., Seibert K. Regulation of prostaglandin synthesis by glucocorticoids. Receptor. 4:1994;25-30.
85. Mayhan W.G. Regulation of blood-brain barrier permeability. Microcirculation. 8:2001;89-104.
86. McDonald D.M. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am. J. Respir. Crit. Care Med. 164:2001;S39-S45.
87. McDonald D.M., Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res. 62:2002;5381-5385.
88. Metz C., Sibbald W.J. Anti-inflammatory therapy for acute lung injury. A review of animal and clinical studies. Chest. 100:1991;1110-1119.
89. Miyamoto K., Khosrof S., Bursell S.E., Rohan R., Murata T., Clermont A.C., Aiello L.P., Ogura Y., Adamis A.P. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc. Natl. Acad. Sci. U. S. A. 96:1999;10836-10841.
90. Moy A.B., Bodmer J.E., Blackwell K., Shasby S., Shasby D.M. cAMP protects endothelial barrier function independent of inhibiting MLC20-dependent tension development. Am. J. Physiol. 274:1998;L1024-L1029.
91. Mulligan M.S., Warner R.L., Rittershaus C.W., Thomas L.J., Ryan U.S., Foreman K.E., Crouch L.D., Till G.O., Ward P.A. Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewis x moieties. J. Immunol. 162:1999;4952-4959.
92. Nakajima M., Cooney M.J., Tu A.H., Chang K.Y., Cao J., Ando A., An G.J., Melia M., de Juan E.J. Normalization of retinal vascular permeability in experimental diabetes with genistein. Invest. Ophthalmol. Vis. Sci. 42:2001;2110-2114.
93. Netti P.A., Hamberg L.M., Babich J.W., Kierstead D., Graham W., Hunter G.J., Wolf G.L., Fischman A., Boucher Y., Jain R.K. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl. Acad. Sci. U. S. A. 96:1999;3137-3142.
94. Nielsen L.B. Transfer of low density lipoprotein into the arterial wall and the risk of atherosclerosis. Arteriosclerosis. 123:1996;1-15.
95. Ningaraj N.S., Rao M., Hashizume K., Asotra K., Black K.L. Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J. Pharmacol. Exp. Ther. 301:2002;838-851.
96. Noll T., Wozniak G. Factor XIII and endothelial barrier function. Hämostaseologie. 22:2002;28-31.
97. i. Am. J. Physiol. 276:1999;H1892-H1901.
98. Noll T., Wozniak G., McCarson K., Hajimohammad A., Metzner H.J., Inserte J., Kummer W., Hehrlain F.W., Piper H.M. Effect of Factor XIII on endothelial barrier function. J. Exp. Med. 189:1999;1373-1382.
99. Noll T., Schafer M., Schavier-Schmitz U., Piper H.M. ATP induces dephosphorylation of myosin light chain in endothelial cells. Am. J. Physiol. Cell Physiol. 279:2000;C717-C723.
100. Nurnberger W., Heying R., Burdach S., Gobel U. C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation. Ann. Hematol. 75:1997;95-101.
101. Nzeako U.C., Frigas E., Tremaine W.J. Hereditary angioedema: a broad review for clinicians. Arch. Intern. Med. 161:2001;2417-2429.
102. Ohki S., Iizuka K., Ishikawa S., Kano M., Dobashi K., Yoshii A., Shimizu Y., Mori M., Morishita Y. A highly selective inhibitor of Rho-associated coiled-coil forming protein kinase, Y-27632, prolongs cardiac allograft survival of the BALB/c-to-C3H/He mouse model. J. Heart Lung Transplant. 20:2001;956-963.
103. Okuda Y., Tsurumaru K., Suzuki S., Miyauchi T., Asano M., Hong Y., Sone H., Fujita R., Mizutani M., Kawakami Y., Nakajima T., Soma M., Matsuo K., Suzuki H., Yamashita K. Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sci. 63:1998;477-484.
104. Ostrovsky L., Woodman R.C., Payne D., Teoh D., Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation. 96:1997;2302-2310.
105. Oura H., Silva J., Velasco P., Brown L.F., Carmeliet P., Detmar M. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood. 101:2003;560-567.
106. Palmer G.C. Neurochemical coupled actions of transmitters in the microvasculature of the brain. Neurosci. Biobehav. Rev. 10:1986;79-101.
107. Panetti T.S. Differential effects of sphingosine 1-phosphate and lysophosphatidic acid on endothelial cells. Biochim. Biophys. Acta. 1582:2002;190-196.
108. Park J.E., Chen H.H., Winer J., Houck K.A., Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269:1994;25646-25654.
109. Paul R., Zhang Z.G., Eliceiri B.P., Jiang Q., Boccia A.D., Zhang R.L., Chopp M., Cheresh D.A. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat. Med. 7:2001;222-227.
110. Pedram A., Razandi M., Levin E.R. Deciphering vascular endothelial cell growth factor/vascular permeability factor signaling to vascular permeability. Inhibition by atrial natriuretic peptide. J. Biol. Chem. 277:2002;44385-44398.
111. Persson C.G. The action of beta-receptors on microvascular endothelium or: is airways plasma exudation inhibited by beta-agonists? Life Sci. 52:1993;2111-2121.
112. Pietras K., Rubin K., Sjoblom T., Buchdunger E., Sjoquist M., Heldin C.H., Ostman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62:2002;5476-5484.
113. Porter L.P., McNamee J.E., Wolf M.B. Endothelin-1 induces endothelial barrier failure in the cat hindlimb. Shock. 11:1999;111-114.
114. Pruefer D., Scalia R., Lefer A.M. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. 19:1999;2894-2900.
115. Rapoport S.I. Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy. Expert Opin. Investig. Drugs. 10:2001;1809-1818.
116. Reinhart K., Menges T., Gardlund B., Harm Z.J., Smithes M., Vincent J.L., Tellado J.M., Salgado-Remigio A., Zimlichman R., Withington S., Tschaikowsky K., Brase R., Damas P., Kupper H., Kempeni J., Eiselstein J., Kaul M. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: the RAMSES study. Crit. Care Med. 29:2001;765-769.
117. Repka-Ramirez M.S., Baraniuk J.N. Histamine in health and disease. Clin. Allergy Immunol. 17:1902;1-25.
118. Rippe B., Grega G.J. Effects of isoprenaline and cooling on histamine induced changes of capillary permeability in the rat hindquarter vascular bed. Acta Physiol. Scand. 103:1978;252-262.
119. Salven P., Hattori K., Heissig B., Rafii S. Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J. 16:2002;1471-1473.
120. Scalia R., Gooszen M.E., Jones S.P., Hoffmeyer M., Rimmer D.M., Trocha S.D., Huang P.L., Smith M.B., Lefer A.M., Lefer D.J. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation. 103:2001;2598-2603.
121. Schmidt W., Stenzel K., Gebhard M.M., Martin E., Schmidt H. C1-esterase inhibitor and its effects on endotoxin-induced leukocyte adherence and plasma extravasation in postcapillary venules. Surgery. 125:1999;280-287.
122. Schwartz M.A. Integrin signaling revisited. Trends Cell Biol. 11:2001;466-470.
123. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:1983;983-985.
124. Seto M., Sasaki Y., Hidaka H. Effects of HA1077, a protein kinase inhibitor, on myosin phosphorylation and tension in smooth muscle. Eur. J. Pharmacol. 195:1991;267-272.
125. Shanley T.P., Warner R.L., Ward P.A. The role of cytokines and adhesion molecules in the development of inflammatory injury. Mol. Med. Today. 1:1995;40-45.
126. Shiels I.A., Zhang S., Ambler J., Taylor S.M. Vascular leakage stimulates phenotype alteration in ocular cells, contributing to the pathology of proliferative vitreoretinopathy. Med. Hypotheses. 50:1998;113-117.
127. Shiels I.A., Taylor S.M., Fairlie D.P. Cell phenotype as a target of drug therapy in chronic inflammatory diseases. Med. Hypotheses. 54:2000;193-197.
128. Shimokawa H., Seto M., Katsumata N., Amano M., Kozai T., Yamawaki T., Kuwata K., Kandabashi T., Egashira K., Ikegaki I., Asano T., Kaibuchi K., Takeshita A. Rho kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc. Res. 43:1999;1029-1039.
129. Shimokawa H., Hiramori K., Iinuma H., Hosoda S., Kishida H., Osada H., Katagiri T., Yamauchi K., Yui Y., Minamino T., Nakashima M., Kato K. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J. Cardiovasc. Pharmacol. 40:2002;751-761.
130. Siegal T., Zylber-Katz E. Strategies for increasing drug delivery to the brain: focus on brain lymphoma. Clin. Pharmacokinet. 41:1902;171-186.
131. Siess W. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim. Biophys. Acta. 1582:2002;204-215.
132. Stelzner T.J., Weil J.V., O'Brien R.F. Role of cyclic adenosine monophosphate in the induction of endothelial barrier properties. J. Cell. Physiol. 139:1989;157-166.
133. Sun Z., Wang X., Lasson A., Bojesson A., Annborn M., Andersson R. Effects of inhibition of PAF, ICAM-1 and PECAM-1 on gut barrier failure caused by intestinal ischemia and reperfusion. Scand. J. Gastroenterol. 36:2001;55-65.
134. Suttorp N., Weber U., Welsch T., Schudt C. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J. Clin. Invest. 91:1993;1421-1428.
135. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 22:2002;143-152.
136. Thurston G., Suri C., Smith K., McClain J., Sato T.N., Yancopoulos G.D., McDonald D.M. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 286:1999;2511-2514.
137. Thurston G., Rudge J.S., Ioffe E., Zhou H., Ross L., Croll S.D., Glazer N., Holash J., McDonald D.M., Yancopoulos G.D. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 6:2000;460-463.
138. Tinsley J.H., Wu M.H., Ma W., Taulman A.C., Yuan S.Y. Activated neutrophils induce hyperpermeability and phosphorylation of adherens junction proteins in coronary venular endothelial cells. J. Biol. Chem. 274:1999;24930-24934.
139. 2+ signaling in the regulation of endothelial permeability. Vasc. Pharmacol. 39:2003;173-185.
140. Turegun M., Gudemez E., Newman P., Zins J., Siemionow M. Blockade of platelet endothelial cell adhesion molecule-1 (PECAM-1) protects against ischemia-reperfusion injury in muscle flaps at microcirculatory level. Plast. Reconstr. Surg. 104:1999;1033-1040.
141. Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., Tamakawa H., Yamagami K., Inui J., Maekawa M., Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 389:1997;990-994.
142. Van Nieuw Amerongen G.P., Van Hinsbergh V.W.M. Cytoskeletal effects of rho-like small guanine nucleotide-binding proteins in the vascular system. Arterioscler. Thromb. Vasc. Biol. 21:2001;300-311.
143. Van Nieuw Amerongen G.P., Vermeer M.A., Negre-Aminou P., Lankelma J., Emeis J.J., Van Hinsbergh V.W.M. Simvastatin improves disturbed endothelial barrier function. Circulation. 102:2000;2803-2809.
144. Victorino G.P., Wisner D.H., Tucker V.L. Direct actions of endothelin-1 on single vessel hydraulic permeability. J. Trauma. 47:1999;713-718.
145. Vogel S.M., Gao X., Mehta D., Ye R.D., John T.A., Andrade-Gordon P., Tiruppathi C., Malik A.B. Abrogation of thrombin-induced increase in pulmonary microvascular permeability in PAR-1 knockout mice. Physiol. Genomics. 4:2000;137-145.
146. Warren K.E., Patel M.C., Aikin A.A., Widemann B., Libucha M., Adamson P.C., Neuwirth R., Benziger D., O'Toole T., Ford K., Patronas N., Packer R.J., Balis F.M. Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. Cancer Chemother. Pharmacol. 48:2001;275-282.
147. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7:2001;687-692.
148. Wettschureck N., Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J. Mol. Med. 80:2002;629-638.
149. Whittles C.E., Pocock T.M., Wedge S.R., Kendrew J., Hennequin L.F., Harper S., Bates D.O. ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. Microcirculation. 9:1902;513-522.
150. Wojciak-Stothard B., Ridley A.J. Rho GTPases and the regulation of endothelial permeability. Vasc. Pharmacol. 39:2003;187-199. (this issue).
151. Wood J.M., Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., Hofmann F., Mestan J., Mett H., O'Reilly T., Persohn E., Rosel J., Schnell C., Stover D., Theuer A., Towbin H., Wenger F., Woods-Cook K., Menrad A., Siemeister G., Schirner M., Thierauch K.H., Schneider M.R., Drevs J., Martiny-Baron G., Totzke F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60:2000;2178-2189.
152. Wozniak G., Noll T., Akinturk H., Thul J., Muller M. Factor XIII prevents development of myocardial edema in children undergoing surgery for congenital heart disease. Ann. N. Y. Acad. Sci. 936:1902;617-620.
153. Xia P., Aiello L.P., Ishii H., Jiang Z.Y., Park D.J., Robinson G.S., Takagi H., Newsome W.P., Jirousek M.R., King G.L. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. 98:1996;2018-2026.
154. Yamaki K., Thorlacius H., Xie X., Lindbom L., Hedqvist P., Raud J. Characteristics of histamine-induced leukocyte rolling in the undisturbed microcirculation of the rat mesentery. Br. J. Pharmacol. 123:1998;390-399.
155. 2+ channels. J. Hypertens. Suppl. 6:1988;S188-S191.
156. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 420:2002;78-84.
157. Yuan S.Y. Protein kinase signaling in the modulation of microvascular permeability. Vasc. Pharmacol. 39:2003;213-223.
158. Zimmerman R.S., Trippodo N.C., MacPhee A.A., Martinez A.J., Barbee R.W. High-dose atrial natriuretic factor enhances albumin escape from the systemic but not the pulmonary circulation. Circ. Res. 67:1990;461-468.
159. Zlokovic B.V., Apuzzo M.L. Cellular and molecular neurosurgery: pathways from concept to reality: Part II. Vector systems and delivery methodologies for gene therapy of the central nervous system. Neurosurgery. 40:1997;805-812.
160. Zylber-Katz E., Gomori J.M., Schwartz A., Lossos A., Bokstein F., Siegal T. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Clin. Pharmacol. Ther. 67:2000;631-641.